Indication
Juvenile Chronic Myelogenous Leukemia
1 clinical trial
3 products
1 drug
Clinical trial
Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058)Status: Recruiting, Estimated PCD: 2028-12-01
Product
TrametinibProduct
AzacitidineDrug
fludarabineProduct
Cytarabine